Page 89 - 51 the significance--29.2_opt

Table 2. Ongoing CV outcome studies investigating the CV safety of T2DM treatments

Clinical Trial. gov identifier NCT00790205 NCT00968708 NCT01107886 NCT00069784 NCT01243424 NCT01032629 NCT01131676 NCT01144338 NCT01179048

Primary outcome measures Assess the impact of sitagliptin as part of usual care vs. usual care without sitagliptin on prima- ry composite CV endpoint (CV-related death, non-fatal myocardial infarction, non-fatal stroke, or unstable angina requiring hospitalization) Time from randomization to the occurrence of the primary

Patients enrolled 14,000 5,400 12,000 stroke 12,500 6,000 4,332 4,000 9,500 stroke) 8,754

Start and end date Dec 2008 – Dec 2014* Sep 2009 – Dec 2014 May 2010 – May 2015 Sep 2003 – Dec 2011 Oct 2010 – Sep 2018 Dec 2009 – Apr 2013 Dec 2010 – Aug 2014 Jun 2010 – Mar 2017 Aug 2010 – Jan 2016

To determine if including sitagliptin as part of usual care has any impact upon a composite CV endpoint To determine the CV outcomes of alogliptin, once daily, compared with placebo, in addition to standard of care, in subjects with T2DM and acute coronary To determine if saxagliptin can reduce the risk of CV events

Aim syndrome medications IFG, IGT or early T2DM outcome against glimepiride

Trial name TECOS 54 EXAMINE 55 SAVOR- TIMI 53 56 ORIGIN 57 CAROLINA 58 CANVAS BI 10773 CV Outcome Event Trial in T2DM 59 EXSCEL 60 LEADER 61

89